AHEAD Advate in HaEmophilia A outcome Database

被引:0
|
作者
Oldenburg, J. [1 ]
Kurnik, K. [2 ]
Huth-Kuhne, A. [3 ]
Zimmermann, R. [3 ]
Abraham, I.
Klamroth, R. [4 ]
机构
[1] Univ Klinikum Bonn, Inst Expt Hamatol & Transfus Med, Bonn, Germany
[2] Univ Munich, Dr von Haunersches Kinderspital, D-80539 Munich, Germany
[3] Kurpfalzkrankenhaus Heidelberg, Hamophiliezentrum, Heidelberg, Germany
[4] Vivantes Klinikum Friedrichshain, Klin Innere Med Angiol & Hamostaseol, Hamophiliezentrum, Berlin, Germany
来源
HAMOSTASEOLOGIE | 2010年 / 30卷 / 4A期
关键词
Haemophilia; Advate; AHEAD; outcome;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The clinical picture of haemophilia A patients is often characterised by recurrent bleedings, in particular joint bleeds Thus far, long-term data on the outcome of haemophilia A patients are scarce as regards the development of target joints, joint replacement, lost days from school or work due to bleedings, and the quality of life, as most previous studies were limited to the aspects of safety and efficacy The Baxter-initiated AHEAD (Advate in HaEmophilia A outcome Database) study is a multi-centre, prospective, non-interventional observational study of haemophilia A patients All patients with a residual FVIII activity of <= 5% who are being treated with ADVATE are eligible There are no limitations in terms of patient age or treatment regimen AHEAD is scientifically supported by a renowned interdisciplinary steering board and is intended to yield data on 500 patients in up to 30 haemophilia centres, collected during a period of four years The large patient population has been chosen in order to ensure a valid database The objective of the study is to record haemophilia-related arthropathies, which will be defined based on imaging techniques (e g MRI, X-ray, ultrasound) and the judgment of the attending physician In addition, extensive data will be collected on joint replacement surgeries, pseudotumour development, bleeding-related pain, quality of life (age-related questionnaires Haem-A-QoL, Haemo-Qol, SF10, SF12v2), risk factors (diabetes mellitus, arterial hypertension, nicotine abuse), blood group, gene mutation, physical activity, and on the efficacy and safety of Advate The patient data will be entered into an electronic CRF system at the centres Plausibility checks during data entry, regular monitoring visits, and the option of auditing all serve to ensure a high data quality for AHEAD The first patient was enrolled in the study in early June 2010, recruitment is planned to continue until the end of 2011 The Ethics Committee of the University of Bonn has given its favorable opinion
引用
收藏
页码:S23 / S25
页数:3
相关论文
共 50 条
  • [31] The effect of resistance exercise on strength and safety outcome for people with haemophilia: A systematic review
    Wagner, Barbara
    Krueger, Steffen
    Hilberg, Thomas
    Ay, Cihan
    Hasenoehrl, Timothy
    Huber, Dominikus Franz-Xaver
    Crevenna, Richard
    HAEMOPHILIA, 2020, 26 (02) : 200 - 215
  • [32] Outcome of CARE: a 6-year national registry of acquired haemophilia A in China
    Sun, Boyang
    Xue, Feng
    Feng, Ying
    Sun, Jing
    Yu, Ziqiang
    Hou, Ming
    Zhang, Jingyu
    Zeng, Xiaojing
    Zhao, Yongqiang
    Lian, Shimei
    Huang, Meijuan
    Niu, Ting
    Cui, Zhongguang
    Wu, Jingsheng
    Yang, Renchi
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 187 (05) : 653 - 665
  • [33] Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project
    Iorio, A.
    Skinner, M. W.
    Clearfield, E.
    Messner, D.
    Pierce, G. F.
    Witkop, M.
    Tunis, S.
    HAEMOPHILIA, 2018, 24 (04) : E167 - E172
  • [34] Analysis of haemophilia B database and strategies for identification of common point mutations in the factor IX gene
    Mukherjee, S
    Mukhopadhyay, A
    Chaudhuri, K
    Ray, K
    HAEMOPHILIA, 2003, 9 (02) : 187 - 192
  • [35] An observational study of haemophilia A patients without inhibitors using the French national claims (SNDS) database
    Trossaert, Marc
    Falk, Aletta
    Gautier, Laurene
    Kragh, Nana
    Van Hinloopen, Olivia
    Varin, Remi
    HEMATOLOGY, 2024, 29 (01)
  • [36] Registry-based outcome assessment in haemophilia: a scoping study to explore the available evidence
    Osooli, M.
    Berntorp, E.
    JOURNAL OF INTERNAL MEDICINE, 2016, 279 (06) : 502 - 514
  • [37] Low risk of inhibitor formation in haemophilia A patients following en masse switch in treatment to a third generation full length plasma and albumin-free recombinant factor VIII product (ADVATE®)
    Bacon, C. L.
    Singleton, E.
    Brady, B.
    White, B.
    Nolan, B.
    Gilmore, R. M.
    Ryan, C.
    Keohane, C.
    Jenkins, P. Vince
    O'Donnell, J. S.
    HAEMOPHILIA, 2011, 17 (03) : 407 - 411
  • [38] Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry
    Spinar, Jindrich
    Parenica, Jiri
    Vitovec, Jiri
    Widimsky, Petr
    Linhart, Ales
    Fedorco, Marian
    Malek, Filip
    Cihalik, Cestmir
    Spinarova, Lenka
    Miklik, Roman
    Felsoci, Marian
    Bambuch, Miroslav
    Dusek, Ladislav
    Jarkovsky, Jiri
    CRITICAL CARE, 2011, 15 (06):
  • [39] Identifying performance-based outcome measures of physical function in people with haemophilia (IPOP)
    Bladen, Melanie
    Harbidge, Hannah
    Drechsler, Wendy
    Duport, Gaetan
    Mahaffey, Ryan
    van der Net, Janjap
    Perez-Alenda, Sofia
    Sayers, Fionnuala
    Strike, Karen
    Timmer, Merel
    Stephensen, David
    HAEMOPHILIA, 2023, 29 (06) : 1611 - 1620
  • [40] Baseline characteristics and hospital mortality in the Acute Heart Failure Database (AHEAD) Main registry
    Jindrich Spinar
    Jiri Parenica
    Jiri Vitovec
    Petr Widimsky
    Ales Linhart
    Marian Fedorco
    Filip Malek
    Cestmír Cihalik
    Lenka Spinarová
    Roman Miklik
    Marian Felsoci
    Miroslav Bambuch
    Ladislav Dusek
    Jiri Jarkovsky
    Critical Care, 15